EU "instruction" takes effect

According to the latest information from the China Import and Export Association of Health Care Products, China's exports of proprietary Chinese medicines to the European Union amounted to US$ 8,605,800, a year-on-year increase of 51.16%, but in the “Regulations on Traditional Plant Drug Registration Procedures” (below Shortly after the "instruction" came into effect on April 30, 2011, from May to June, China's exports of Chinese patent medicines to the European Union were US$1.7615 million, a year-on-year decrease of 23.69%. The Medicare Chamber of Commerce pointed out that the negative impact of the Directive on the export of proprietary Chinese medicines to the EU has begun to manifest itself.

In the first half of the year, China's exports of proprietary Chinese medicines to the EU were US$ 8,605,800, which represented a growth rate of more than half year-on-year, and the Medicare Chamber of Commerce analyzed that this was mainly due to the fact that some companies completed their export transactions in order to catch up with the EU's “instruction” deadline. . The United Kingdom is the main market for imports of Chinese proprietary Chinese medicine products in the European Union. Prior to the entry into force of the Directive, British sellers sold a large amount of goods. The above factors have led to an increase in exports of Chinese patent medicines to the EU in the first half of the year.

According to reports, on March 31, 2004, the European Union issued the "Directive," which stipulates that traditional herbs "have at least 30 years of medicinal history before the filing date, including at least 15 years of use history in the European Community". , and set a seven-year transitional period to allow the sale of herbal products sold in European Union countries in various capacities such as food, botanical raw materials or agricultural and sideline products to March 31, 2011, during which time the use of traditional herbal medicines is allowed to be simplified. Apply for access to medicines for their legal status.

Relying on the advantage curve of Hong Kong Chinese medicine transit station

Liu Zhanglin, deputy director of the China Chamber of Commerce for the Import and Export of Medicines and Health Products, said that although some domestic Chinese medicine companies in China have submitted application materials to the European Union, for a variety of reasons, no one company has passed the simplified registration of the European Union's "Directive." In view of this, the chamber of commerce has been continuously communicating with the pharmaceutical regulatory authorities in major countries in the European Union in an attempt to extend the effective time limit for directives against Chinese companies, but it is difficult to promote adjustments to foreign regulations. A staff member from Beijing Tong Ren Tang (600085) said that it is very difficult for China's pharmaceutical companies to apply for registration of plant drugs in the EU. Restricted by the "30-year medical history" and "at least 15 years of use history in the EU" and other regulations, as well as high registration fees, it is difficult for domestic products to enter the EU. From a subjective perspective, Europe still lacks cultural recognition for Chinese medicine.

To this end, experts suggest that hope should not be completely pinned on the outside. Enterprises should also start from within. Relevant departments should accelerate the foreign registration of traditional Chinese medicines to protect the intellectual property rights of Chinese medicine; standardize the cultivation, processing, and sales of traditional Chinese medicine; improve China's exports. Traditional Chinese medicine products are adapted to the requirements of the exporting country regulations and the market. There is also the advantage of using Hong Kong’s Free Harbor, and the curve can save itself.

According to the Medical Insurance Chamber of Commerce, Hong Kong is the most concentrated area of ​​Chinese patent medicine exports. The first half of this year saw exports grow 19.78% year-on-year. The first reason is that Hong Kong’s local consumer demand for proprietary Chinese medicines is strong; second, some Hong Kong merchants are in countries such as the United States and Europe. With branch offices, Hong Kong has become a transit station for Chinese patent medicines for global exports. Through this window in Hong Kong, it will help European customers learn more about Chinese medicine.